UPPSALA, Sweden, May 25, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management will participate in the following investor events:
A live and archived webcast of the Goldman Sachs Global Healthcare Conference will be available on the “Events” section of the Company’s website at https://investors.olink.com/news-events/events.
Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.
IR contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$23.97 |
Daily Change: | 0.04 0.17 |
Daily Volume: | 412,266 |
Market Cap: | US$2.980B |
May 13, 2024 November 15, 2023 November 05, 2023 October 05, 2023 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB